Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor

被引：20

作者：

Imaeda, Yasuhiro ^{[1
]}

Tokuhara, Hidekazu ^{[1
]}

Fukase, Yoshiyuki ^{[1
]}

Kanagawa, Ray ^{[1
]}

Kajimoto, Yumiko ^{[1
]}

Kusumoto, Keiji ^{[1
]}

Kondo, Mitsuyo ^{[1
]}

Snell, Gyorgy ^{[2
]}

Behnke, Craig A. ^{[2
,3
]}

Kuroita, Takanobu ^{[1
]}

机构：

[1] Takeda Pharmaceut Co Ltd, Pharmaceut Res Div, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan

[2] Takeda Calif Inc, 10410 Sci Ctr Dr, San Diego, CA 92121 USA

[3] Sapphire Energy Inc, 9363 Towne Ctr Dr, San Diego, CA 92121 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 10期

基金：

美国国家卫生研究院;

关键词：

Renin inhibitor; TAK-272; benzimidazole; hypertension; SBDD; dTg rat; HYPERTENSION; PIPERIDINES; EFFICIENCY; ALISKIREN; DESIGN; SYSTEM;

D O I：

10.1021/acsmedchemlett.6b00251

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1' site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials.

引用

页码：933 / 938

页数：6

共 50 条

[21] AN ORALLY ACTIVE INHIBITOR OF HUMAN RENIN
KOKUBU, T
HIWADA, K
MURAKAMI, E
MUNETA, S
KITAMI, Y
MORISAWA, Y
KOIKE, H
TAKAHAGI, H
IIJIMA, Y
NISHIMURA, K
SALMON, PF
HYPERTENSION, 1989, 14 (03) : 357 - 357
[22] Aliskiren: An orally active renin inhibitor
Wal, Pranay
Wal, Ankita
Rai, Awani K.
Dixit, Anuj
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2011, 3 (02): : 189 - 193
[23] DISCOVERY OF A NOVEL AND POTENT CHOLESTEROL ABSORPTION INHIBITOR (CAI) AS PROMISING ORALLY ACTIVE LIPID LOWERING DRUG
Kanou, M.
Nisiwaki, Y.
Nakano, A.
Sugimoto, Y.
Yamanaka, Y.
Kondo, S.
ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
[24] FK-906, A HIGHLY POTENT, ORALLY-ACTIVE HUMAN RENIN INHIBITOR
NEYA, M
MARUSAWA, H
IMAL, K
KAYAKIRI, N
WATANABE, S
HEMML, K
HASHIMOTO, M
TANAKA, H
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 56 - MEDI
[25] Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates
Coassolo, P
Fischli, W
Clozel, JP
Chou, RC
XENOBIOTICA, 1996, 26 (03) : 333 - 345
[26] Discovery of DS79182026: A potent orally active hepcidin production inhibitor
Fukuda, Takeshi
Goto, Riki
Kiho, Toshihiro
Ueda, Kenjiro
Muramatsu, Sumie
Hashimoto, Masami
Aid, Anri
Watanabe, Kengo
Tanaka, Naoki
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (16) : 3716 - 3722
[27] Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor
Nakamura, Yuji
Fujimoto, Teppei
Ogawa, Yasuyuki
Sugita, Chie
Miyazaki, Shojiro
Tamaki, Kazuhiko
Takahashi, Mizuki
Matsui, Yumi
Nagayama, Takahiro
Manabe, Kenichi
Mizuno, Makoto
Masubuchi, Noriko
Chiba, Katsuyoshi
Nishi, Takahide
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 754 - 758
[28] ANTIHYPERTENSIVE EFFICACY OF PD-134672 - A NOVEL ORALLY ACTIVE RENIN INHIBITOR
RYAN, MJ
BATLEY, BL
HICKS, GW
PAINCHAUD, CA
RAPUNDALO, ST
TAYLOR, DG
FASEB JOURNAL, 1991, 5 (06): : A1575 - A1575
[29] Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor
He, Pengxing
Niu, Shenghui
Wang, Shuai
Shi, Xiaojing
Feng, Siqi
Du, Linna
Zhang, Xuyang
Ma, Zhilu
Yu, Bin
Liu, Hongmin
ACTA PHARMACEUTICA SINICA B, 2019, 9 (06) : 1193 - 1203
[30] Discovery of WS-157 as a highly potent,selective and orally active EGFR inhibitor
Pengxing He
Shenghui Niu
Shuai Wang
Xiaojing Shi
Siqi Feng
Linna Du
Xuyang Zhang
Zhilu Ma
Bin Yu
Hongmin Liu
Acta Pharmaceutica Sinica B, 2019, 9 (06) : 1193 - 1203

← 1 2 3 4 5 →